The estimated Net Worth of Sean E George is at least $12.4 Million dollars as of 16 December 2022. Sean George owns over 55,979 units of Invitae Corp stock worth over $14,654 and over the last 10 years he sold NVTA stock worth over $7,029,103. In addition, he makes $5,319,510 as Chairman of the Board, President, Chief Executive Officer, and Co-Founder at Invitae Corp.
Sean has made over 31 trades of the Invitae Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 55,979 units of NVTA stock worth $114,757 on 16 December 2022.
The largest trade he's ever made was selling 55,979 units of Invitae Corp stock on 16 December 2022 worth over $114,757. On average, Sean trades about 12,417 units every 62 days since 2015. As of 16 December 2022 he still owns at least 732,677 units of Invitae Corp stock.
You can see the complete history of Sean George stock trades at the bottom of the page.
Dr. Sean E. George Ph.D. serves as Chairman of the Board, President, Chief Executive Officer, Co-Founder of the Company. Sean E. George, Ph.D. is one of our co-founders and has been our President and Chief Executive Officer since January 2017, a position he previously held from January 2010 through August 2012. Dr. George served as our President since August 2012, and he has served as our Chief Operating Officer from August 2012 until January 2017. He has also served as a director since January 2010. Prior to co-founding Invitae, Dr. George served as Chief Operating Officer from 2007 to November 2009 at Navigenics, Inc., a personalized medicine company. Previously, he served as Senior Vice President of Marketing and Senior Vice President, Life Science Business at Affymetrix, Inc., a provider of life science and molecular diagnostic products, as well as Vice President, Labeling and Detection Business at Invitrogen Corporation, a provider of tools to the life sciences industry, during his tenure there from 2002 to 2007. Dr. George holds a B.S. in Microbiology and Molecular Genetics from the University of California Los Angeles, an M.S. in Molecular and Cellular Biology from the University of California Santa Barbara, and a Ph.D. in Molecular Genetics from the University of California Santa Cruz. George’s perspective as our founder and his current role as President and Chief Executive Officer qualify him to serve on our board of directors.
As the Chairman of the Board, President, Chief Executive Officer, and Co-Founder of Invitae Corp, the total compensation of Sean George at Invitae Corp is $5,319,510. There are no executives at Invitae Corp getting paid more.
Sean George is 46, he's been the Chairman of the Board, President, Chief Executive Officer, and Co-Founder of Invitae Corp since 2019. There are 16 older and 3 younger executives at Invitae Corp. The oldest executive at Invitae Corp is Dr. Robert L. Nussbaum, 71, who is the Chief Medical Officer.
Sean's mailing address filed with the SEC is C/O INVITAE CORPORATION, 1400 16TH STREET, SAN FRANCISCO, CA, 94103.
Over the last 10 years, insiders at Invitae Corp have traded over $68,349,838 worth of Invitae Corp stock and bought 2,982,686 units worth $18,086,236 . The most active insiders traders include Bros. Advisors Lp Baker Bro..., Bros. Advisors Lpbaker Feli..., and James E Deerfield Mgmt L.P..... On average, Invitae Corp executives and independent directors trade stock every 14 days with the average trade being worth of $540. The most recent stock trade was executed by Robert L Nussbaum on 13 June 2023, trading 7,086 units of NVTA stock currently worth $9,779.
invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people. specializing in genetic diagnostics for hereditary disorders, invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today. choose from our curated panels or design your own test for the same low price. today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. together we can improve healthcare for billions of people.
Invitae Corp executives and other stock owners filed with the SEC include: